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A B S T R A C T
Polymeric nanoparticles is an established and efﬁcient means to achieve controlled release of drugs.
Incorporation of minocycline, an antibiotic with anti-inﬂammatory and neuroprotective properties, into
biodegradable nanoparticles may therefore provide an efﬁcient means to combat foreign body reactions
to implanted electrodes in the brain. However, minocycline is commonly associated with poor
encapsulation efﬁciencies and/or fast release rates due to its high solubility in water. Moreover,
minocycline is unstable under conditions of low and high pH, heat and exposure to light, which
exacerbate the challenges of encapsulation. In this work drug loaded PLGA nanoparticles were prepared
by a modiﬁed emulsiﬁcation-solvent-diffusion technique and characterized for size, drug encapsulation
and in vitro drug release. A novel hydrophobic ion pair complex of minocycline, Ca2+ ions and the anionic
surfactant AOT was developed to protect minocycline from degradation and prolong its release. The
optimized formulation resulted in particle sizes around 220 nm with an entrapment efﬁciency of 43% and
showed drug release over 30 days in artiﬁcial cerebrospinal ﬂuid. The present results constitute a
substantial increase in release time compared to what has hitherto been achieved for minocycline and
indicate that such particles might provide useful for sustained drug delivery in the CNS.
ã 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
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Minocycline, a broad-spectrum antibiotic with anti-inﬂamma-
tory properties, has been shown to have neuroprotective and
neurorestorative effects in ischemic injury/stroke and neurode-
generative disease models (Lee et al., 2004; Ryu et al., 2004). The
mechanisms behind these effects are believed to lay in minocycline
’s ability to inhibit proliferation and activation of reactive microglia
(Giuliani et al., 2005; McAllister Ii and Miller, 2010; Tikka et al.,
2001). The neuroprotective role of minocycline has been used to
improve the quality and longevity of chronic neural recordings by
reducing glial sheath growth on implanted microelectrodes in the
central nervous system (CNS) (Rennaker et al., 2007). However, the
effects were only seen at high doses by conventional administra-
tion due to the molecules restricted passage over the blood–brain-* Corresponding author at: Neuronano Research Center, Department of
Experimental Medical Science, Medical Faculty, Lund University, Medicon Village,
404 A2, Scheelevägen 2, SE 223 81 Lund, Sweden.
E-mail address: Alexander.Holmkvist@med.lu.se (A.D. Holmkvist).
http://dx.doi.org/10.1016/j.ijpharm.2016.01.011
0378-5173/ã 2016 The Authors. Published by Elsevier B.V. This is an open access articbarrier (Pardridge, 2005) and short half-life (Di Stefano et al.,
2008).
To improve the therapeutic efﬁcacy and decrease the drug dose
required from minocycline and other water-soluble drugs, local
delivery from biodegradable nanoparticles could be used (Orive
et al., 2009). One of the most widely used biodegradable material
for drug delivery is poly(D,L-lactic-co-glycolic acid) (PLGA) as it
undergoes hydrolysis in the body to produce the metabolite
monomers, lactic acid and glycolic acid. Since the body effectively
deals with these, there is minimal systemic toxicity associated
with using PLGA for drug delivery even in the CNS (Houchin and
Topp, 2008; Kumari et al., 2010). The PLGA particles can be
designed to give a sustained release over a period of days or even
weeks after implantation. Hence, such a sustained release of
minocycline from nanoparticles would be ideal for reducing the
foreign body response seen after implanting electrodes in the brain
(Polikov et al., 2005).
Encapsulation of water-soluble drugs into PLGA nanoparticles is
generally done by double emulsion techniques (Astete and Sabliov,
2006). This approach often yields high encapsulation efﬁcienciesle under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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wetted upon contact with aqueous media, which subsequently
results in faster release rates (Fredenberg et al., 2011; Siepmann
et al., 2005). Using homogenous particles where the drug is
entrapped throughout the particle matrix is preferable in this
sense (Klose et al., 2006; Stevanovic and Uskokovic, 2009).
Preparation of these is usually based on single oil-in-water (o/
w) emulsiﬁcation methods, such as the emulsiﬁcation-solvent-
diffusion (ESD) technique (Kwon et al., 2001; Pinto Reis et al., 2006;
Quintanar-Guerrero et al.,1997) schematically shown in Fig.1. Both
drug and polymer are ﬁrst dissolved in an organic solvent followed
by emulsiﬁcation into an aqueous phase containing a surfactant. A
large amount of water is then added to the system leading to
solvent diffusion to the external phase and the formation of
nanospheres. Finally the solvent is evaporated, resulting in a stable
colloidal suspension containing nanoparticles of solid polymer
stabilized by the surfactant. The surfactant type and concentration
will have a large impact on the ﬁnal particle size and affects the
drug loading efﬁciency (Gómez-Gaete et al., 2007), sphericity
(Esposito et al., 1999) and surface charge of the formed particles
(Italia et al., 2007). A commonly used surfactant for this
preparation method is didodecyldimethylammonium bromide
(DMAB), a double-chain compound belonging to the class of
cationic quaternary ammonium surfactants (Kwon et al., 2001).
Cationic surface charges are desirable as it promotes interaction of
the nanoparticles with cells and hence increases the rate and
extent of internalization (Kumari et al., 2010). The ESD technique
presents several advantages, such as high batch-to-batch repro-
ducibility, simplicity and narrow size distribution. Disadvantages
are the large volumes of water to be eliminated from the
suspension and the leakage of water-soluble drugs into the
aqueous external phase during emulsiﬁcation. Drug leakage will
result in low encapsulation and can lead to a high initial burst
release (Danhier et al., 2012) if the leaked drug adsorbs onto the
surface of the particles rather than being dispersed throughout the
polymer matrix. Another contributing factor for low encapsulation
efﬁciency is degradation of the drug during preparation (Xu et al.,
2009). Minocycline is known to be unstable under acidic or
alkaline conditions, heat and exposure to light, where it undergoes
epimerization and degrades (Chow et al., 2008; Zbinovsky and
Chrekian, 1977). Studies have however shown that chelation ofFig. 1. (A) Schematic representation of PLGA nanoparticle preparation by the ESD-tec
entrapped drug is distributed throughout the polymer matrix and the particles surface i
ions and bis(2-ethylhexyl) sulfosuccinate (AOT).minocycline with Ca2+ signiﬁcantly enhances the stability of the
drug in solution (Soliman et al., 2010).
Unlike other tetracyclines, minocycline contains two amino
groups that are responsible for its high solubility in water. In total,
it has four ionizable groups with the dissociation constants of
pKa1 = 2.8; pKa2 = 5.0; pKa3 = 7.8; and pKa4 = 9.3 (Kalish and Koujak,
2004). The isoelectric point of minocycline is at pH 6.4 were the
molecules neutral zwitterionic form is predominant and the
highest partition coefﬁcient in octanol is found (Zbinovsky and
Chrekian, 1977). The high aqueous solubility of ionic compounds
stems not only from being charged, but also from the fact that the
counter ions easily solvates by water. If the counter ion would be
replaced with a species with similar charge, but less solvated by
water it is expected that the aqueous solubility would decrease.
This process is referred to as hydrophobic ion pairing (HIP)
(Jacobson et al., 2010; Meyer and Manning, 1998) and involves
stoichiometric replacement of polar counter ions with ionic
detergents of similar charge.
The purpose of this study was to prepare DMAB stabilized
minocycline-loaded PLGA nanoparticles by the ESD-method,
aiming for particle sizes around 100 nm, high encapsulation
efﬁciencies and long release times. We have evaluated two
approaches to increase minocycline’s solubility in organic solvents
by replacing the water-soluble hydrochloride salt form of
minocycline with either its isoelectric form at pH 6.4 or a HIP-
complex of minocycline, Ca2+ and the anionic surfactant bis(2-
ethylhexyl) sulfosuccinate (AOT), an FDA approved food additive
(Fig. 1C). The prepared nanoparticles were characterized for size,
morphology, drug loading and in vitro drug release.
2. Materials and methods
All samples were prepared in triplicate and tested with triple
measurements or more. Data is presented as the mean  standard
deviation of the mean.
2.1. Materials
Poly(D,L-lactic-co-glycolic acid) (PLGA) (50:50), Mw 24000-
38000 acid terminated (Sigma). Minocycline hydrochloride
(Sigma–Aldrich). Didodecyldimethylammonium bromide (DMAB)hnique. (B) Proposed composition of the formed drug-loaded nanoparticles; the
s covered with the cationic surfactant DMAB. (C) HIP-complex of minocycline, Ca2+
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sulfosuccinate (AOT) (D4422, Sigma–Aldrich) was used as an ion
pairing agent. HEPES-buffered artiﬁcial cerebrospinal ﬂuid pH 7.3
(aCSF) (Protocols, 2011) was used as drug release medium. All
other chemicals and solvents used were of HPLC grade. Milli Q
ultra-pure water (Millipore) was exclusively used for the
preparation of all aqueous solutions.
2.2. Preparation of nanoparticles
Nanoparticles were prepared by an ESD technique (Quintanar-
Guerrero et al., 1997). In brief, PLGA (20 mg) was dissolved in an
ethyl acetate/methanol mixture (9:1, 1 ml) at room temperature.
The organic phase was added drop-wise to a bis–tris buffered
aqueous solution (10 mM, pH 6.4) containing a stabilizer (DMAB,
0.10%, 1.2 ml) under magnetic stirring at 600 rmp. The two-phase
system was then emulsiﬁed by sonication for 10 minutes using an
iced ultra-sonic cleaning bath (VWR USC 300 D, 80 W at 45 kHz). To
this emulsion, water (12 ml) was added under constant stirring,
which resulted in nanoprecipitation. The suspension was then kept
in an open beaker with magnetic stirring (400–500 rpm) overnight
to evaporate the organic solvent. To prepare drug-loaded nano-
particles, minocycline was dissolved together with PLGA in the
organic phase following the same protocol. The inﬂuence of
altering the following formulation parameters was investigated
and optimized with respect to particle size and drug incorporation,
aiming for particle sizes around 100 nm and high encapsulation
efﬁciency.
DMAB concentration
Blank nanoparticles were prepared using different DMAB
concentrations (0.01–0.15%) in bis–tris buffered water phase
(10 mM, pH 6.4) and then evaluated for size and zeta potential.
Preparation of nanoparticles with the isoelectric form of minocy-
cline at pH 6.4
Minocycline was dissolved in water and set to its isoelectric
point at pH 6.4 by addition of 0.2 M NaOH. Minocycline at its
isoelectric point was extracted with dichloromethane (DCM) and
the solvent was evaporated under reduced pressure. Particle
preparation was performed as described above and three different
drug-to-polymer (D/P) ratios (5, 12.5 and 20%) were evaluated.
Preparation of nanoparticles with a HIP complex of minocycline,
Ca2+ and AOT
The HIP complexation was accomplished according to Soliman
et al. (2010) and the Bligh-Dyer method (Bligh and Dyer, 1959) in a
monophase of dichloromethane, water, and methanol. Stock
solutions of CaCl2 and minocycline were prepared in Tris–HCl
buffer (102M, pH 7.4). The pH of the solutions was adjusted to
7.4 using 0.1 M NaOH, if necessary. The CaCl2 solution was added to
the minocycline solution at speciﬁc volume to attain a minocy-
cline/Ca2+ molar ratio of 1:2. This solution was then added to an
equal volume of DCM containing an equimolar amount of AOT with
respect to the Ca2+ ions. A mono-phase was formed by addition of
methanol at volume ratios of 1:1:2.1 of (buffer/DCM/methanol).
The solution mixture was ﬁnally phase separated by addition of
equal volumes of buffer (1 ml) and DCM (1 ml) followed by
centrifugation at 1000 rcf for 1.5 minutes, with the minocycline/
Ca2+/AOT-complex now present in the organic phase. The complex
was isolated by separation of the two phases and evaporation of
the solvent. 1H NMR spectra of the formed complex were recorded
on a Bruker Avance II 400 MHz spectrometer in deuterated
chloroform (CDCl3) at room temperature. Chemical shifts are
given in ppm downﬁeld from the signal for Me4Si, with reference to
residual CDCl3. Control samples of minocycline, minocycline/Ca2+
(molar ratio 1:2), AOT, and minocycline/AOT (molar ratio 1:2) all
subjected to the same method were also recorded. Particle
preparation was performed as described above except for theuse of Tris–HCl buffer (102M, pH 7.4) instead of bis–tris buffer in
all aqueous solutions. Five different D/P ratios (1, 1.5, 2, 3 and 4%)
were evaluated.
2.3. Particle size and morphology
The hydrodynamic size, polydispersity index (PDI) and zeta
potential of the prepared nanoparticles was determined by
dynamic light scattering (Malvern Zetasizer Nano-ZS), taking the
average of three measurements for each batch. The suspensions
were diluted ten times with the aqueous phase used in the
formulation before measurements. The morphology of the nano-
particles was investigated by SEM (FEI Nova NanoLab 600) at a
working distance to 5.2 mm and an accelerating voltage of 15 kV.
The sample was prepared by spin-coating the ﬁltered crude
suspension on a silicon wafer at 2000 rpm for 1 min.
2.4. Drug encapsulation
Centrifugation was used to separate the drug-loaded nano-
particles from the residual free drug in the suspensions. All
nanoparticle suspensions were ﬁltered through a sintered glass
ﬁlter before the separation. The suspensions were centrifuged
(Centrifuge 5430, Eppendorf) at 7197 rcf for 30 min, the superna-
tant was discarded and the pellet was resuspended in pure water,
three times. The washed nanoparticles were ﬁnally frozen in liquid
nitrogen and lyophilized at 55 C and 0.050 mbar for 12 h
(Freezone 4.5 model 77510, Labconco). The freeze-dried nano-
particles (NPs) were weighted and dissolved in acetonitrile (0.1%
TFA, 400 ml). Methanol (0.1% TFA, 1 ml) was then added to dissolve
the drug and precipitate the polymer. The solution was centrifuged
at 1000 rcf for 5 min and the supernatant was ﬁltered through a
0.45 mm Teﬂon ﬁlter. The amount of minocycline was quantiﬁed by
HPLC (Hewlett-Packard LC 1100 Series, Agilent Technologies,
Foster City, CA, USA) at 25 C using a Xterra MS 50  2.1 mm,
2.5 mm particle size reversed phase C18 column (Waters, Millford,
CT, USA). A mobile phase gradient program was used starting at
95% triﬂuoroacetic acid (0.05%), gradually changing over to 30%
acetonitrile in 4 min and then ﬁnishing by changing to 95%
acetonitrile in one minute at the ﬂow rate of 0.27 ml/min. An
injection volume of 5 ml and a detection wavelength of 354 nm
were used. Linear calibration curves (r2 0.999) were obtained
over the drug concentration range of 2–20 mg/ml.
The drug encapsulation is expressed both as drug content (DC)
and entrapment efﬁciency (EE), represented by Eqs. (1) and (2) and
respectively.
DC ð%Þ ¼ mass of drug in NPs
mass of freeze  dried NPs 100 ð1Þ
EE ð%Þ ¼ actual drug content
theoretical drug content
 100 ð2Þ
2.5. Drug release
The drug release from the optimized 3% minocycline/Ca2+/AOT-
formulation was studied in vitro using a dialysis technique. Three
batches of freshly prepared nanoparticle suspensions (total
volume of 42 ml, containing 60 mg PLGA and 1.8 mg minocycline)
were combined, ﬁltered through a glass ﬁlter and lyophilized.
Mannitol (2% w/v) and Pluronic F-127 (1%, 3 ml) were used as
cryoprotectants to enable redispersion and prevent particle
aggregation. The freeze-dried nanoparticles were resuspended
in 5 ml of aCSF and placed in a dialysis bag (SnakeSkin, 10K MWCO,
Thermo Scientiﬁc, Rockford, IL, USA). The dialysis bag was then
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tained at 37 C in a water bath. At predetermined time intervals, the
whole release medium was replaced with fresh medium. The
released amount of minocycline was quantiﬁed by HPLC at 25 C
using a Sunﬁre 100  3.0 mm, 3.5 mm particle size reversed phase
C18 column (Waters, Millford, CT, USA). An isocratic mobile phase
of triﬂuoroacetic acid (0.05%)-acetonitrile at the volume ratio of
87:13 and ﬂow rate of 0.6 ml/min was used. All samples were
ﬁltered through a 0.20 mm Teﬂon ﬁlter. An injection volume of
20 ml and a detection wavelength of 354 nm were used. Linear
calibration curves (r2 0.980) were obtained over the drug
concentration range of 1–10 mg/ml. Evaluation of the dialysis
method described above was done by measuring minocycline’s
diffusion over the dialysis bags in two different setups; minocy-
cline only and minocycline together with cryoprotectants in aCSF.
The stability and degradation of minocycline in aCSF (25, 50 and
100 mg/ml) under the in vitro release conditions was also
investigated in a seven-day study.
3. Results and discussion
3.1. Particle size and morphology
Initial studies were made on the surfactants effect on size and
morphology. Drug free nanoparticles were prepared using differ-
ent DMAB concentrations and evaluated for size, PDI and zeta
potential. The PDI is a dimensionless measure of the broadness of
the size distribution calculated from a cumulants analysis of the
DLS-measured intensity autocorrelation function. In the Zetasizer
software the PDI ranges from 0 to 1. Numerically, a dispersion may
be considered monodisperse if 90% of the distribution lies within
5% of the average size. The PDI typically has values less than
0.1 for a monodisperse test sample (ISO-22412:2008). Values
greater than 0.7 indicate that the sample has a very broad size
distribution and is probably not suitable for the dynamic light
scattering (DLS) technique. As can be seen in Table 1, formulations
with DMAB concentrations lower than 0.10% resulted in larger
particles with broader size distributions (PDI > 0.1), negative zeta
potentials and/or unsuccessful emulsions. Formulations with
DMAB concentrations of 0.10% and higher resulted in monodis-
perse nanoparticles (PDI < 0.1) with positive zeta potentials. The
mean particle size was 150 nm in diameter and decreasing with
increasing surfactant concentrations.
The amount of surfactant used during particle preparation is an
important factor for both size reduction and stability of the
prepared nanoparticle suspensions. Too low concentration leads to
aggregation of the polymer, whereas too high concentration may
affect drug incorporation as a result of the interaction between
drug and stabilizer. The zeta potential gives information on the
stability of the prepared nanoparticle suspensions and is strongly
inﬂuenced by the particles surface charge and hence the type of
surfactant being used. Particles with large negative or positive zeta
potentials (> 30 mV) will form stable colloidal suspensions since
they tend to repel each other and thereby reduce aggregation.Table 1
Effect of DMAB concentration on size, PDI and zeta potential (mean  s.d., n = 3).
DMAB conc. (% w/v) Size (d. nm) PDI Zeta pot. (mV)
0.01 Aggregation – –
0.025 Aggregation – –
0.05 900  200 0.50  0.08 58  7
0.075 3400  500 0.39  0.09 2  8
0.10 150  10 0.06  0.02 +57  7
0.125 140  2 0.05  0.02 +75  4
0.15 124  2 0.06  0.01 +80  5Generally, PLGA nanoparticles generate negative zeta potentials
due to the PLGA’s free carboxylic end groups (Kuo and Yu, 2011;
Stolnik et al., 1995). Here, the zeta potential shifted to positive
values with increasing surfactant concentration most likely as an
effect of the increasing surface coverage of DMAB on the prepared
particles.
It should be noted that the 0.05% and 0.075% formulations
initially formed visibly stable suspensions. These suspensions,
however, started to ﬂocculate with time and the reported sizes are
more likely of agglomerated nanoparticles, as indicated by their
higher PDI-values. A possible explanation is that the amount of
surfactant was sufﬁcient to stabilize the dispersed droplets of
solvent in the o/w emulsion and enable the nanoparticle formation
during preparation but insufﬁcient to stabilize the formed
nanoparticles in the ﬁnal suspension. Therefore the zeta potential
for these formulations more likely represents that of the formed
agglomerates and not of the nanoparticles.
The surfactant concentration should be kept to a minimum to
reduce the risk of interactions between drug and surfactant, but yet
high enough to prevent particle aggregation stabilize the
suspensions. A DMAB concentration of 0.10% was therefore used
in all subsequent formulations. Our optimized HIP-complex
formulation with a theoretical D/P ratio of 3% generated a positive
zeta potential of 55  4 mV and somewhat larger particles as
compared to the blank formulation (220 nm and 150 nm,
respectively). This is illustrated by the size distribution curves
generated via DLS in Fig. 2. The more or less unchanged zeta
potential of the HIP-complex formulation compared to the blank
(+55 mV and +57 mV, respectively), indicate that there was no
interaction between drug and particle surface.
All size measurements were performed using DLS, which
reports the size of a hypothetical hard sphere that diffuses in the
same fashion as that of the particle being measured. In order to
validate the size results obtained with DLS, the overall shape of the
nanoparticles was investigated by SEM imaging. The SEM micro-
graphs in Fig. 2 conﬁrm that both the blank and the HIP-complex
loaded nanoparticles were spherical.Fig. 2. DLS size distribution curves and SEM micrographs of blank and drug-loaded*
PLGA nanoparticles prepared with the same DMAB concentration (0.10%). Note that
the number of image pixels and signal-to-noise ratio are limited for these SEM
images due to a high sensitivity of the nanoparticles to radiation damage. *A
minocycline/Ca2+/AOT-complex at a theoretical D/P ratio of 3% was used.
Table 2
Effect of drug form and D/P ratio on size, PDI, drug content (DC) and entrapment
efﬁciency (EE) (mean  s.d. n = 3).
Drug form D/P ratio (%) Size (d. nm) PDI DC (%) EE (%)
MC pH 6.4 5 159  4 0.04  0.01 0.06  0.01 1.4  0.2
12.5 161  2 0.04  0.02 0.16  0.02 1.5
 0.2
20 145  4 0.05  0.02 0.26  0.03 1.6  0.2
MC/Ca2
+/AOT
1 180  5 0.04  0.02 0.11  0.02 12  2
1.5 190  10 0.08  0.03 0.27  0.05 20  4
2 195  1 0.06  0.01 0.82  0.04 43  2
3 220  6 0.07  0.04 1.12  0.01 43  1
4 700  600 0.4  0.1 – –
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To obtain nanoparticles with high entrapment efﬁciencies by
the ESD-method, a key parameter is controlling the drugs
solubility in organic solvents. To increase minocycline’s (MC)
lipophilicity, we attempted to replace the hydrochloride salt form
with either the isoelectric form (MC pH 6.4) or the HIP-complex
(MC/Ca2+/AOT). Furthermore, different D/P ratios were evaluatedFig. 3. 1H NMR spectra in CDCl3 at room temperature: (A) MC; (B) MC/Ca2+; (C) AOT;
(D) MC/Ca2+/AOT; (E) MC/AOT.for optimizing the drug encapsulation. Table 2 summarizes the
effect of different combinations on particle size, PDI, drug content
and entrapment efﬁciency. All formulations except the 4% HIP-
complex, resulted in monodisperse particles (PDI < 0.1) with mean
sizes below 220 nm. The lowest entrapment efﬁciencies were
obtained by the isoelectric approach, most likely because the drug
is still very water-soluble in the zwitterionic state and diffuses
easily into the external aqueous phase during preparation. The
isoelectric formulations were therefore excluded from all further
characterization. The highest drug content and entrapment
efﬁciency (1.12% and 43%, respectively) were achieved with the
HIP-complex in combination with a D/P ratio of 3%. This compares
with others in the ﬁeld who have achieved 1.92% and 29.95%,
respectively, for ion paired PLGA–PEG-dextran sulphate nano-
particles (Kashi et al., 2012) and 9.3% and 46.5%, respectively, for
sodium cholate stabilized PEG–PLA nanoparticles (Yao et al., 2014).
1H NMR spectra of the HIP-complex and control samples are shown
in Fig. 3. Comparison of chromatogram (A) and (B) show changes in
intensity and shape for minocycline’s characteristic peaks at 5.95,
6.83, 7.31, 9.50, 11.53 and 14.87 ppm, which indicates minocycline
complexation with Ca2+ ions. Comparison of chromatogram (C)
and (D) show a broadening of AOT’s characteristic peaks at 3.74–
3.98 ppm in the presence of the minocycline/Ca2+ chelate, strongly
suggesting that a minocycline/Ca2+/AOT-complex has formed.
Chromatogram (E) of AOT and minocycline in the absences of
Ca2+ appears as a combination of chromatogram (A) and (C),
indicating no interaction occurs between minocycline and AOT in
the absence of Ca2+ ions.
Two different buffering agents were used during particle
preparation, as they are useful in different pH ranges; bis–tris (pH
range 5.8–7.2) was used in the blank and iso-electric formulations
at pH 6.4, and Tris–HCl (pH range 7–9) was used in the HIP-
complex formulations at pH 7.4. The choice of buffering agent
could have effects on particle characteristics such as size and drug
content. The results presented in Tables 1 and 2 however, indicate
that the size increase seen for HIP-complex loaded nanoparticles is
more likely an effect of increased drug content rather than an effect
of using a different buffering agent.
3.3. In vitro drug release
The drug release was quantiﬁed in vitro by a dialysis method.
Unwashed nanoparticles were used both to mimic the future
handling of the formulations, and to prevent morphological
changes and premature drug release, which a washing step using
centrifugal forces might induce (Moreno-Bautista and Tam, 2011).
The release proﬁle of minocycline from minocycline/Ca2+/AOT-
complex loaded PLGA nanoparticles with a theoretical D/P ratio of
3% (Fig. 4) show an initial burst during the ﬁrst 24 h followed by a
linear release over 30 days. Since unwashed particles were used,
the initial spike in drug release is due to unencapsulated drug. The
subsequent slow release is more likely caused by drug diffusion
and erosion of the polymeric matrix. Cryoprotectants were added
before freeze-drying to prevent the nanoparticles from agglomer-
ating and should be regarded as a part of the formulation. After
resuspension, the initial mannitol and Pluronic F-127 concentra-
tion inside the dialysis bags were approx. 22% and 0.5%,
respectively. Effect of cryoprotectants on minocycline’s diffusion
through the dialysis bags and the release curves are shown in Fig. 4.
The release for only minocycline show that more than 98% of the
free drug was released within two days, which follows the
expected release kinetics from a dialysis bag when replacing the
surrounding release medium at each sampling point and assuming
unhindered diffusion. When cryoprotectants were present how-
ever, six days were required for 98% of total drug content release,
which most likely is an effect of the initial high mannitol
Fig. 4. In vitro release from minocycline/Ca2+/AOT-complex loaded PLGA nano-
particles with a theoretical D/P ratio of 3% and control curves of minocycline only
and minocycline together with cryoprotectants.
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viscosity and thereby a slower intrinsic diffusion. Pluronic F-127 is
not likely to affect the viscosity at such low concentrations (Gilbert
et al., 1986). The slower intrinsic diffusion is also likely to occur in
the nanoparticle release study but will presumably level of with
time as the mannitol molecule is small enough to diffuse through
the dialysis tubing. There were no measured differences in
replaced amount of release medium between the three different
cases and no visual observations of osmotic pressure building up
inside the bags during the release study, which also supports this
assumption. The minocycline concentration was evidently higher
inside than outside the dialysis bag during the ﬁrst sampling points
when cryoprotecants were present. This could slow down the
diffusion of drug molecule from the drug carrier as the
concentration gradient between inside particle and the interior
of dialysis bag is lower. Due to these diffusional barriers the initial
drug release may be lower in the generated curve than it would be
if samples ware taken from inside the dialysis bags. This may in
turn also slow down the overall release from the particles and give
rise to a slightly longer release proﬁle. The choice of aCSF as release
medium stemmed not only from the prospective application area,
the brain, but also for its high content of protective divalent cations
(Mg2+ and Ca2+). No degradation of minocycline was detected in
aCSF during the seven-day stability study (data not shown).
Furthermore, since the sampling interval was never longer than
three days and the entire release medium outside the dialysis bags
was replaced at each sampling time, there was no need to
compensate the release curve for degradation. The fact that
minocycline was detectable even after 30 days suggests that the
HIP-complex was dispersed throughout the polymeric matrix
rather than adsorbed to the surface of the particles. The long
release time also suggest that minocycline is protected from
degradation when encapsulated in this form, despite the risk of
creating an acidic milieu inside the particle as the polymer is
hydrolysed (Houchin and Topp, 2008).
The present results constitute a substantial increase in release
time compared to what has hitherto been achieved for minocy-
cline-loaded polymeric nanoparticles. For example, Kashi et al.
(2012), who investigated different methods for preparing PLGA
nanoparticles containing minocycline, showed an in vitro drug
release in phosphate- buffered saline (PBS; pH 7.4) over ﬁve days
by an ion pairing technique with PLGA-PEG-dextran sulphate. Yaoet al. (2014) reported a release time of 14 days in PBS (0.01 M, pH
7.4) from their sodium cholate stabilized PEG-PLA nanoparticles
which could be ideal for periodontal disease treatment. Our longer
release proﬁle over 30 days, however, provide a better match with
respect to the normal time course of brain tissue responses
associated with implantation of electrodes (Polikov et al., 2005). It
should be noted that a comparison of in vitro drug-release proﬁles
with others could be misleading, as no standard testing procedures
are used. The in vitro release methods and test conditions are often
chosen with regard to the prospective environment the colloids are
intended for, which may affect the release kinetics. The biological
activity of the released minocycline from our minocycline/Ca2
+/AOT loaded PLGA nanoparticles remains to be evaluated in vivo.
Prior to clinical use, aspects such as surfactant toxicity and residual
solvent content should also be assessed (Dixit et al., 2015).
4. Conclusion
In this work, minocycline-loaded PLGA nanoparticles were
prepared by a single oil-in-water based preparation technique and
characterized for size, drug entrapment and in vitro drug release.
The inﬂuence of various formulation parameters was investigated
and optimized with respect to particle size and drug incorporation.
Introduction of a novel HIP-complex of minocycline, Ca2+ and AOT
resulted in monodisperse particles around 220 nm in size, high
encapsulation efﬁciency (43%) and long in vitro drug release
(>30 days). Our results demonstrate that hydrophobic ion pairing
with AOT is an effective strategy to incorporate minocycline into
PLGA nanoparticles and could further be applicable to other water-
soluble drugs. The high encapsulation efﬁciency and prolonged
release proﬁle in artiﬁcial CSF suggests that the particles may be
useful to accomplish sustained and local delivery of minocycline in
the CNS. We propose that such nanoparticles delivered from
implanted electrodes in the brain may be used to reduce the
foreign body responses and protect the nearby neurones.
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